Related Experiment Video
Updated: Aug 10, 2026
08:05
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
Autonomous AI in prostate cancer: the road ahead towards clinical implementation
Lisa D Koopmans1, Fernando Vega Lara2, Christian Roest2
1Department of Radiology, University Medical Center Groningen, Groningen, Netherlands. l.d.koopmans@umcg.nl.
Abdominal Radiology (New York)
|August 8, 2026
Summary
Artificial intelligence (AI) shows promise for detecting prostate cancer on MRI, matching radiologist accuracy. However, technical and societal barriers, including limited evidence and acceptance, hinder its clinical deployment.
Area of Science:
- Medical imaging analysis
- Artificial intelligence in healthcare
- Prostate cancer diagnostics
Background:
- AI achieves radiologist-level performance in detecting clinically significant prostate cancer (csPCa) on MRI.
- AI offers potential workflow efficiencies and solutions for imaging demands and radiologist shortages.
Purpose of the Study:
- To explore technical and societal barriers to the clinical deployment of autonomous AI for csPCa detection.
- To identify challenges in evidence base, safety, and stakeholder perspectives.
Main Methods:
- Narrative review focusing on limitations in the evidence base.
- Examination of safety issues and mitigation strategies.
- Analysis of patient and radiologist perspectives.
Main Results:
- Need for large, multicenter, prospective trials and robust evaluation frameworks.
- Requirement for safeguards to manage data mismatches during AI deployment.
- Limited acceptance of autonomous AI by patients and radiologists, influenced by transparency, education, and medico-legal clarity.
Conclusions:
- Addressing evidence gaps, safety concerns, and stakeholder acceptance is crucial for responsible AI deployment.
- Overcoming these barriers is essential to realize AI's efficiency benefits in clinical practice for prostate cancer detection.
